Delaware
(State or other jurisdiction of incorporation)
|
1-08323
(Commission File Number)
|
06-1059331
(IRS Employer
Identification No.)
|
Cigna Corporation
|
||
Date: February 4, 2013
|
By:
|
/s/ Ralph J. Nicoletti |
Ralph J. Nicoletti
|
||
Executive Vice President
|
||
and Chief Financial Officer
|
NEWS RELEASE
|
![]() |
Contacts:
|
Ted Detrick, Investor Relations – (215) 761-1414, Edwin.Detrick@cigna.com
|
|
Matthew Asensio, Media Relations – (860) 226-2599, Matthew.Asensio@cigna.com
|
o
|
Funds transaction with Berkshire Hathaway through $100 million of incremental parent company cash, along with assets supporting the business and the related tax benefit
|
1.
|
increased medical costs that are higher than anticipated in establishing premium rates in the Company’s Global Health Care operations, including increased use and costs of medical services;
|
2.
|
increased medical, administrative, technology or other costs resulting from new legislative and regulatory requirements imposed on the Company’s businesses;
|
3.
|
challenges and risks associated with implementing improvement initiatives and strategic actions in the ongoing operations of the businesses, including those related to: (i) growth in targeted geographies, product lines, buying segments and distribution channels, (ii) offering products that meet emerging market needs, (iii) strengthening underwriting and pricing effectiveness, (iv) strengthening medical cost results and a growing medical customer base, (v) delivering quality service to members and health care professionals using effective technology solutions, and (vi) lowering administrative costs;
|
4.
|
adverse changes in state, federal and international laws and regulations, including health care reform legislation and regulation that could, among other items, affect the way the Company does business, increase costs, limit the ability to effectively estimate, price for and manage medical costs, and affect the Company’s products, services, market segments, technology and processes;
|
5.
|
the ability to successfully complete the integration of acquired businesses, including the acquired HealthSpring businesses by, among other things, operating Medicare Advantage coordinated care plans and HealthSpring’s prescription drug plan, retaining and growing the customer base, realizing revenue, expense and other synergies, renewing contracts on competitive terms, successfully leveraging the information technology platform of the acquired businesses, and retaining key personnel;
|
6.
|
the ability of the Company to execute its growth plans by successfully leveraging its capabilities and those of the businesses acquired in serving the Seniors market segment and the Company’s other market segments, including through successful execution of the Company’s physician engagement strategy;
|
7.
|
the possibility that the acquired HealthSpring business may be adversely affected by economic, business and/or competitive factors; or by federal and/or state regulation, including health care reform, reductions in funding levels for Medicare programs, and potential changes in risk adjustment data validation audit and payment adjustment methodology;
|
8.
|
risks associated with pending and potential state and federal class action lawsuits, disputes regarding reinsurance arrangements, other litigation and regulatory actions challenging the Company’s businesses, including disputes related to payments to health care professionals, government investigations and proceedings, tax audits and related litigation, and regulatory market conduct and other reviews, audits and investigations;
|
9.
|
heightened competition, particularly price competition, that could reduce product margins and constrain growth in the Company’s businesses, primarily the Global Health Care business;
|
10.
|
risks associated with the Company’s mail order pharmacy business that, among other things, includes any potential operational deficiencies or service issues as well as loss or suspension of state pharmacy licenses;
|
11.
|
significant changes in interest rates or sustained deterioration in the commercial real estate markets;
|
12.
|
downgrades in the financial strength ratings of the Company’s insurance subsidiaries, that could, among other things, adversely affect new sales and retention of current business; downgrades in financial strength ratings of reinsurers or adjustments to the assumptions used in estimating the liabilities for the Company's reinsurance contracts, that could result in increased statutory reserves or capital requirements of the Company’s insurance subsidiaries;
|
13.
|
limitations on the ability of the Company’s insurance subsidiaries to dividend capital to the parent company as a result of downgrades in the subsidiaries’ financial strength ratings, changes in statutory reserve or capital requirements or other financial constraints;
|
14.
|
risks associated with the reinsurance transaction for the run-off guaranteed minimum death benefits and guaranteed minimum income benefits businesses, including the risk that future liabilities exceed the cap under the reinsurance agreement or that the reinsurance does not otherwise provide adequate protection;
|
15.
|
significant stock market declines, that could, among other things, impact the Company’s pension plans in future periods as well as the recognition of additional pension obligations;
|
16.
|
significant deterioration in economic conditions and significant market volatility, that could have an adverse effect on the Company’s operations, investments, liquidity and access to capital markets;
|
17.
|
significant deterioration in economic conditions and significant market volatility, that could have an adverse effect on the businesses of our customers (including the amount and type of health care services provided to their workforce, loss in workforce and our customers' ability to pay their obligations) and our vendors (including their ability to provide services);
|
18.
|
amendments to income tax laws, that could affect the taxation of employer-provided benefits and the taxation of certain insurance products such as corporate-owned life insurance;
|
19.
|
potential public health epidemics, pandemics, natural disasters and bio-terrorist activity, that could, among other things, cause the Company’s covered medical and disability expenses, pharmacy costs and mortality experience to rise significantly, and cause operational disruption, depending on the severity of the event and number of individuals affected;
|
20.
|
risks associated with security or interruption of information systems, that could, among other things, cause operational disruption;
|
21.
|
challenges and risks associated with the successful management of the Company’s outsourcing projects or key vendors; and
|
22.
|
the unique political, legal, operational, regulatory and other challenges associated with expanding our business globally.
|
^5?ZD*E8&^0(A#&)$3L-(X1Z-N+\%@..M>
ML8ZM0I,*)FL%KZ1EZV:9!EB;"DO(PJI$'/&L42RMG6.-9FQNB;,K&K*V)[F/
M?&V3Q[TC>^.-SF(OM I4#(!)&/
M1LC'C643FR-;(BH]K53,7'->U3J7DE7NU:]Q!_O(M(5827^R8&UKI9&2L'MJ6R@#N*DE\4K1K($6=T
\H[7QE:R%G6&T1_%5UEWT7Z8VTO&F3RK_`#!J>J0FP[O*7+\X/\_E
MXAXU5RGPUI7,%/%T]P3DB_!6W&XVQC+YT;%8[XUPM?$K=7=#(J5_A]=OA*^X
M>/D?E27K_0][_&&M%)PO`*F!9/8MB?LS&I0VM]RI\JQU